Press releases
The Board of Directors of Lipum AB (publ) (“Lipum”) unanimously recommends the shareholders of Lipum to vote in favour of the completion of...
2025-11-18 08:00
Flerie and Lipum have agreed on a merger plan
THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED...
Lipum AB (publ) today announced topline results from collaborative studies with Senior Associate Professor Alf Kastbom and team at Linköping University...
2025-08-28 08:17
Lipum AB – interim report Q2 for the period January-June 2025
Lipum AB (publ) has published the interim report Q2 for the period January-June 2025. Below is a summary, a complete report (only in Swedish) is available...
2025-08-07 08:30
Lipum Welcomes Tobias Helgesson as New Chief Financial Officer
Lipum AB (publ) has appointed Tobias Helgesson as its new Chief Financial Officer (CFO). He succeeds Marina Norberg, who will remain with the company during...
2025-08-01 15:00
Lipum AB (publ) has decided to postpone the interim report Q2 2025 to August 28, 2025
The previously announced publication date for the interim report Q2 2025 was August 14. The publication has now been postponed to August 28, 2025. Contacts...
Lipum AB (publ) today announces the allocation of warrants in series TO A 2025/2028 and TO B 2025/2028, as resolved at the company’s Annual General...
2025-05-26 08:10
Lipum AB (publ) has published the company’s annual report for the financial year 2024.
The shareholders of Lipum are invited to the Annual General Meeting on June 16, 2025, at 1:00 PM at Lipum’s office, Tvistevägen 48C, 907 36...
2025-04-24 08:00
Lipum AB – interim report Q1 for the period January-March 2025
Lipum AB (publ) has published the interim report Q1 for the period January-March 2025. Below is a summary, a complete report (only in Swedish) is available...
2025-04-11 11:28
Lipum Announces Successful Completion of Phase I Trial for SOL-116 - Supporting Continued Clinical Development
Lipum AB (publ) announces the completion and publication of the Clinical Study Report (CSR) for its First-in-Human (FIH) Phase I trial evaluating SOL-116...